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Background: Fixed-dose combinations of artemisinin combination therapy are strongly recommended to facilitate
drug administration and compliance. New fixed-dose combinations must nevertheless be evaluated in relevant
populations in terms of efficacy and pharmacokinetics.
Methods: A single-arm, open-label, clinical trial was performed in Indian patients with acute uncomplicated Plasmodium
falciparum malaria to investigate the efficacy and the pharmacokinetics of mefloquine when combined with artesunate
in a fixed-dose combination (400/200 mg of mefloquine base/artesunate). The pharmacokinetic analysis was performed
using a population approach.
Results: Seventy-seven patients were included in the study. Mefloquine pharmacokinetics obeys a two-compartment
model with first-order absorption and elimination. Mean parameter estimates (% inter-individual variability) were as
follows: 0.16 h−1 (75%) for the absorption rate constant, 1.13 L/h (30%) for the apparent plasma clearance, 271 L (21%)
for the apparent central distribution volume, 344 L (54%) for the apparent peripheral distribution volume, and 1.43 L/h
for the apparent distribution clearance. These values were consistent with the pharmacokinetic results described in Thai
patients. No significant covariate was found for clearance. Body weight explained the inter-individual variability of the
apparent central and peripheral distribution volumes. The PCR-adjusted efficacy of the treatment was 100%.
Conclusions: The lack of significant covariate explaining the inter-individual variability of mefloquine clearance,
combined with the excellent efficacy, supports the use of the standard 200/400 mg of artesunate-mefloquine
fixed-dose combination in Indian patients with uncomplicated P. falciparum malaria.
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Artemisinin combination therapy (ACT) is now the
treatment of choice for uncomplicated Plasmodium
falciparum malaria [1,2]. These combinations involve a
rapidly eliminated and fast-acting artemisinin derivative,
responsible for a rapid decline in the parasite biomass,
together with a much slower eliminated drug that kills
the remaining parasites. Mefloquine (MQ), is one of the
partner drugs that can be combined with an artemisinin
derivative, with the artesunate (AS)/MQ combination
shown to be effective in several clinical trials [3-5], and
used extensively in countries across Southeast Asia, the
Western Pacific, Africa and Latin America over the last
two decades [6]. The World Health Organization (WHO)
currently recommends five formulations of ACT for
the treatment of uncomplicated P. falciparum malaria,
including the AS and MQ combination [7].
Fixed-dose combinations (FDC) are now strongly
recommended compared to loose tablets because fewer
tablets are involved and patient adherence should be
improved [8]. The FDC of AS/MQ has been demonstrated
to be efficacious and safe for uncomplicated malaria
treatment in studies carried out in Thailand [9], Myanmar
[10], India and Cambodia [11], as well as in a large
intervention study on 23,845 patients in Brazil [12]. It
is nevertheless necessary to verify not only the efficacy but
also the pharmacokinetics of compounds administered as
a FDC in a target population, in order to investigate
possible population-related differences due to metabolism
or food-drug interactions.
The present study investigated the efficacy, tolerability
and pharmacokinetics of the AS/MQ FDC in Indian
adult patients with acute uncomplicated P. falciparum
malaria in highly endemic areas. Despite previous reports
of high degrees of resistance to chloroquine in five Indian
states, no MQ resistance was found [13]. The efficacy
and safety results have already been reported [14], and
here the population pharmacokinetics of mefloquine are
presented.
Methods
An open-label, single arm, multicentre study was carried
out from December 2007 to November 2008 in patients
of more than 18 years of age with P. falciparum malaria
having an asexual parasitaemia density of between 1,000
and 100,000 parasites/μl of blood together with a fever
≥37.5°C. Patients with signs of severe malaria, febrile
conditions due to a disease other than malaria, a history
of anti-malarial treatment in the previous 15 days, anaemia,
hepatic or renal impairment, a history of cardiovascular,
respiratory, gastrointestinal, neurological, malignancy,
psychiatric, or endocrine disorders were excluded.
Pregnant or lactating patients were also excluded. The
study was conducted in accordance with the local lawsand regulations, Indian Good Clinical Practices, Ethical
guidelines on biomedical research issued by the Indian
Council of Medical Research and the International
Conference on Harmonisation-Good Clinical Practices.
The protocol was reviewed and approved by the Ethics
Committee of the National Institute of Malaria Research,
New Delhi, Goa Medical College and Hospitals, Goa and
Kasturba Medical College, Mangalore. Written consent
from each of the subjects were obtained before enrolment
in the study.
Subjects were orally administered two tablets of AS/MQ
FDC, containing 100 mg of AS and 200 mg of MQ base
per tablet, once daily and over three consecutive days.
Blood samples for analysis of MQ plasma concentrations
were collected before dosing on D0, D3 (72 hours after
first dosing), D7, and on one other occasion at a randomly
selected time on day 28, 35 or 42.
An automated liquid chromatography – tandem mass
spectrometry method ( LC-MS/MS) for the quantifica-
tion of AS, MQ and dihydroartemisinin (DHA) levels in
human plasma samples was developed and validated.
These compounds were extracted from human plasma
using a solid phase extraction procedure and injected
into the liquid chromatograph coupled to a tandem
mass spectrometric detector, and quantified by use of
the internal standard method.
MQ was quantified using the Multiple Reaction
Monitoring (MRM) transitions of 379.20➔ 361.atomic
mass units (amu) and amodiaquine as an internal
standard was quantified using MRM transitions of
356.70➔283.20 amu. A weighted linear regression using
weighting 1/concentration2 was prepared to determine
the concentrations of AS, MQ and DHA in human
plasma. Eight-point calibration curves were prepared
(20.2 ng/mL to 1,514.2 ng/mL for AS, 9.9 ng/mL to
3,455.5 ng/mL for MQ, and 39.2 ng/mL to 2,940.0 ng/mL
for DHA), and used to determine concentrations of AS,
MQ and DHA in subject samples. The Lower Limit of
Quantification for MQ (LLOQ) was 9.9 ng/ml.
The bio-analytical method was validated for various
validation parameters, such as specificity and selectivity,
sensitivity, carry-over, solution linearity, precision and
accuracy, recovery, stability, dilution integrity, matrix effect,
re-injection reproducibility, and ruggedness.
During before study method validation for MQ the
within batch precision (% CV) ranged from 2.14% to
6.99% and the between-batch precision ranged from
3.83% to 0.83%. The within batch accuracy (% Nominal)
ranged from 90.91% to 114.41% and the between-batch
accuracy ranged from 99.32 to 104.04%.
The between-run precision (%CV) for the Quality
Control Samples of MQ during the study was 6.49%,
4.16% and 9.11% for LQC, MQC and HQC samples. The
between-run accuracy (% Nominal) for the quality Control
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98.87% for the same samples respectively.
Concentration-time data were analysed by use of the
first-order conditional estimation method with interaction
of the non-linear mixed effects modelling program
NONMEM (version VI, version 2.0, double precision)
[13,15]. Three structural PK models (one, two, and
three compartment models), with first-order absorption
and first-order elimination from the central compart-
ment were investigated. The estimated pharmacokinetic
parameters were the absorption rate constant (ka), the
apparent elimination clearance (CL/F, F being the bio-
availability), the apparent central distribution volume
(Vc/F) and, if relevant, apparent peripheral distribution
volumes (Vp/F for a 2-compartment model, Vp1/F and
Vp2F for a 3-compartment model) and distribution
clearances (Q/F for a 2-compartment model, Q1/F
and Q2/F for a 3-compartment model). Three different
residual errors models (additive, proportional, and com-
bined additive-proportionnal) were tested to investigate
the residual variability. Interindividual variability was
described by an exponential model, assuming that individ-
ual parameters arise from a multivariate lognormal distri-
bution with mean vector and variance-covariance matrix to
be estimated. The % interindividual variability was therefore
calculated as the root mean square of the omega2
value given by NONMEM. Systematic testing for the
influence of continuous covariates on the pharmacokinetic
parameters was done by use of a generalized allometric
model, according to the following equation, by using, for
example, CL/F and BW:
CL
F




where TV(CL/F) was the typical value of the apparent
clearance for a patient with the median covariate value,
and θ was the influential factor for body weight (BW).
Continuous tested covariates for clearance were age,
bodyweight, parasitaemia, hepatic enzymes, haemoglobin,
and serum creatinin. Continuous covariates tested for
distribution volume were bodyweight, haemoglobin,
and parasitaemia.
The possible influence of the day of administration on
CL/F was investigated as follows:
CL
F
¼ TV1 CL F= Þ OCCþ TV2 CL F= Þ  1−OCCð Þ

Where TV1(CL/F) is the mean apparent clearance for
the first two days of treatment and TV2(CL/F) is the
mean apparent clearance for the third day of treatment.OCC(occasion) is equal to 1 for the first two days of
treatment, and otherwise to 0.
The significance of a relationship between a pharma-
cokinetic parameter and a covariate was assessed by use
of the Chi-square test of the difference between the
objective functions of the basic model (without the
covariate) and the model with the covariate. A covariate
was retained in the model if it produced a minimum
decrease in the objective function of 3.64 units (P =0.05, 1
degree of freedom) and if its effect was biologically
plausible. An intermediate multivariate model that included
all selected covariates was then obtained. A covariate was
retained in the final multivariate model if its deletion from
the intermediate model led to a 6.63-point increase in the
objective function (P =0.01, 1 degree of freedom). At each
step, the goodness of fit was evaluated by use of a graph of
the weighted residuals versus time after administration of
the dose (time) or versus the predicted concentrations.
Normalized predictions errors (NPDE) versus time and
predicted concentrations were used to assess the lack of
bias of the final model. NPDE are computed as the
quantiles of the observations in the predicted distribution,
obtained for each observation by simulating 1000 datasets
using the model and the design of the original dataset.
The computation also involves a decorrelation step to
account for the correlation induced by the multiple
observations within one subject. The distribution of
the NPDE under the assumption that the model
describes appropriately the observed data is the standard
Gaussian distribution, and graphs of NDPE versus
time and versus predicted concentrations can be used
to evaluate this assumption [16].
The accuracy and robustness of the final population
models were assessed by a visual predictive check.
The final population model parameters were used to
perform 1000 simulations of the database. The 5th
and the 95th percentiles as well as the 50th (median)
of simulated concentrations were plotted against observed
concentrations.
Bayesian estimates of the individual pharmacokinetic
parameters (obtained in NONMEM output) were used to
calculate individual MQ elimination half-life, the individual
area under the curve from time zero to infinite (AUC), and
MQ concentration at D7 (C7) and D28 (C28). Elimination
half-life was calculated as follows: ln2/β with β = 0.5 ×
(Q/Vc + Q/Vp + CL/Vc-[(Q/Vc + Q/Vp + CL/Vc)2 – 4 ×
Q/Vp x CL/Vc]1/2) and the calculation of C7 and C28
was made by NONMEM.
The primary efficacy outcome of the study was the
PCR-uncorrected cure rate (proportion of patients with
an adequate clinical and parasitological response) on
D63 and PCR-corrected cure rate on D63 (proportion of
patients without recrudescence/ inconclusive/ no results
as classified by PCR genotyping).
Table 1 Characteristics of the study population at the
first drug intake
Mean Standard deviation Range
Age (y) 28.1 9.0 18-45
Body weight (kg) 53.3 7.3 40-70
Parasite density (count/μL) 8356* NR 1165-94693
Haemoglobin (mg/dL) 13.1 2.15 7.1-16.8
ASAT (IU) 34.4 14.1 18-77
ALAT (IU) 26.2 17.1 1-85
Serum creatinine 0.96 0.18 0.6-1.7
*Median; NR: not relevant.
ASAT aspartate aminotransferase; ALAT alanine aminotransferase.
(n = 77: 74 male/3 female).
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success and treatment failure was expected to be performed
by non-parametric statistical analyses.
Results
Seventy-seven patients (74 men, three women) were
included. Their demographic and biological characteristics
are given in Table 1. Three-hundred and fifty-five concen-
trations of MQ were available for the analysis. Distribution
of sampling times can be seen on Figure 1.
The optimal model was a two-compartment model with












Figure 1 Lack of bias evidenced for the final model by the normalize
in hours, and population predictions (PRED).parameters were the absorption rate constant (ka),
the apparent central distribution volume (Vc/F), the
apparent peripheral distribution volume (Vp/F), the
apparent elimination clearance (CL/F), and the apparent
distribution clearance (Q/F), where F is the bioavailability.
Inter-individual variability of Q/F could not be estimated.
Residual variability was described by a proportional
error model.
BW was the only significant covariate and was found
to explain the inter-individual variability of Vp/F and
Vc/F. All other covariates, including the day of dosing was
not found to significantly influence the inter-individual
variability of the PK parameters. The parameter estimates
are given in Table 2.
Epsilon shrinkage was 19.8%, eta shrinkage was 21%
for CL/F, 34% for Vc/F, 53% for Vp/F, and 20% for ka.
The lack of bias of the final model is observed in
Figures 1 and 2. Visual predictive checks for the final
model are displayed in Figure 3 and 11.4% of the observed
concentrations were outside the 90% confidence interval.
Median (range) mefloquine AUC was 1055 (596 – 1741
mg.h/l). Median (range) C7 was 1.58 (1.08 – 2.90) mg/l,
and median (range) C28 was 0.29 (0.11 – 0.57) mg/l.
Since no recrudescence and only one new infection was
observed over the follow-up of the study (PCR-corrected
cure rate of 100%), no correlation between MQ C7 or C28
and treatment efficacy could be investigated.fter dose, h 
predictions, mg/l 
d predictions errors (NPDE) versus time after dose (T1), expressed
Table 2 Parameter estimates
Base model Final model
Parameter Estimate SD Estimate SD
Ka (h−1) 0.166 0.0266 0.163 0.0263
CL/F (L/h) 1.15 0.0496 1.13 0.0501
Vc/F (L) 279 14.7 271 14.1
ѲBW,Vc / / 0.87 0.288
Q/F (L/h) 1.33 0.124 1.43 0.152
Vp/F (L) 341 39 344 40.6
ѲBW,Vp / / 2.41 1.08
ω2ka 0.675 0.250 0.562 0.232
ω2CL
F=
0.0939 0.0224 0.0894 0.0218
ω2Vc
F=
0.0603 0.0209 0.0453 0.0163
ω2Vp
F=
0.401 0.166 0.295 0.128
σ2 0.0689 0.0150 0.0692 0.015
SD standard deviation of the estimate (obtained from the covariance step); Ka:
absorption rate constant; CL/F: apparent oral clearance; Vc/F: apparent central
distribution volume; ѲBW,Vc: influential factor of BW on Vc/F; Q/F: apparent
distribution clearance; Vp/F: apparent distribution volume ; ѲBW,Vp : influential
factor of BW on Vp/F ; ω2CL
F=
: inter-individual variability of CL/F; ω2Vc
F=
:
inter-individual variability of Vc/F; ω2Vp
F=
: inter-individual variability of Vp/F; ω2ka :











Time after dose, h 
Figure 3 Visual predictive checks for the final model. Open
circles: observed concentrations; T1: Time post-dose (hours); red solid
line: 50th percentile of the simulated concentrations; upper blue
dotted line: 95th percentile of the simulated concentrations; lower
blue dotted line: 5th percentile of the simulated concentrations, solid
green line: 50th percentile of observed concentrations, lower and
upper dotted green lines: 5th and 95th percentiles of the observed
concentrations respectively.
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The present model accurately described the data and
was in agreement with previous results seen in adult
patients with uncomplicated malaria (Table 3), even
though the present study was performed on plasma
samples and most of these previous results were based















Figure 2 Population predictions versus observed mefloquine
concentrations. Solid diagonal line: identity (y = x) line.explained by the blood to plasma ratio of MQ which is
close to 1 [17]. This consistency with results from
studies performed in non-Indian patients suggests there
are no ethnic-related differences in MQ pharmacokinetics,
so a similar dosing regimen should achieve similar
concentrations in Thai and in Indian patients. This
result also confirms the bioavailability of the dosage
form used in the present study (a FDC of AS and
MQ) is similar to the bioavailability of the non-fixed
dose MQ forms that were used in previous studies
described by Krudsood et al. [18]. A slightly longer
elimination half-life was found in the present study,
which may be due to differences in study design and
in the sensitivity of the analytical methods. Indeed,
delayed sampling times were available in the present
study, and the quantification of MQ was possible in these
samples thanks to the low LLOQ of the analytical
method (9.9 ng/ml, compared to previous LLOQs of
about 50 ng/ml (Krudsood, Simpson), 70 ng/ml (Ashley),
100 ng/ml (Charles), which allowed the determination of
the two-compartment disposition model.
Differences in study design probably also explain why
no modification in MQ pharmacokinetics during the
treatment administration period could be detected. This
change was previously described and attributed to
the rapid clinical improvement seen due to treatment
Table 3 Pharmacokinetics parameters of mefloquine in the present work and in previous studies
Parameter Gutman et al. [19] Charles et al. [20] Ashley et al. [21] Krudsood et al. [18] Current study









Age (yr): Mean (range)
36 26 19 (Median) 27.8 28
18 - 61 18 - 55 2 - 55 16 - 50 18 -45
BW (kg)
Mean NA 82 44.5 (Median) 51 53.3
Range NA 53 -135 10 - 63 40 - 65 40 - 70
CL/F 0.017 L/h/kg 2.09 L/h 1.33 L/h 0.024 L/h/kg 1.13 L/h
0.022 L/h/kg
V/F 8.57 L/kg 1011 L 488 L NA 615 L
11.9 L/kg














Body weight, kg 
Figure 4 Relationship between mefloquine terminal half-life
(days) and body weight (kg).
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drawn within the first three days of treatment, which
precluded the identification of early changes in MQ
pharmacokinetics.
In agreement with previous findings [20], BW did not
account for the inter-individual variability of MQ CL/F,
so lending support for the current use of a constant
dose, independent of BW, from one adult subject to
another, consistent with previous population pharmaco-
kinetics model performed in adults [20]. These results
contrast with those of Ashley et al. [21], who reported
increasing BW was associated with a reduction in MQ
clearance, however this study included both children
and adults so the relationship between clearance and
BW may have been contributed by the paediatric popu-
lation. Nevertheless, a significant relationship between
BW and the central and peripheral distribution volumes
was found, with a proportional increase in MQ elimin-
ation half-life with increasing BW observed (Figure 4).
The prolonged presence of MQ in subjects with higher
BW may have some impact on the prevention of re-
infection, since it will take more time for MQ levels to
fall below effective concentration levels [23]. However,
the practical consequences of this theoretical finding
should be further investigated. A similar increase in the
clearance and distribution volume of MQ, secondary to
combination with artesunate, and leading to a decrease
in MQ Cmax and AUC of about 25%, was previously
reported by Karbwang et al. [24]. The mechanism of this
interaction could rely on a decrease in the bioavailability
or in the protein binding of MQ. To our knowledge,
this PK interaction was not further investigated.
Anyway, because of the good efficacy of the AS/MQcombination, the clinical relevance of this interaction
is unclear.Conclusions
The present study provided population pharmacokinetics
parameters for MQ, administered as a FDC of AS/MQ,
in Indian adult patients with acute uncomplicated P.
falciparum malaria. The lack of relevant biological covari-
ates on MQ CL/F, combined with the excellent efficacy
results that were obtained, support the use of the 200/400
mg dose of AS/MQ in this population.
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